Inozyme Pharma Stock Alpha and Beta Analysis
| INZY Stock | USD 3.99 0.01 0.25% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Inozyme Pharma. It also helps investors analyze the systematic and unsystematic risks associated with investing in Inozyme Pharma over a specified time horizon. Remember, high Inozyme Pharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Inozyme Pharma's market risk premium analysis include:
Beta 2.14 | Alpha 3.39 | Risk 23.51 | Sharpe Ratio 0.15 | Expected Return 3.42 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Inozyme Pharma Backtesting, Inozyme Pharma Valuation, Inozyme Pharma Correlation, Inozyme Pharma Hype Analysis, Inozyme Pharma Volatility, Inozyme Pharma History and analyze Inozyme Pharma Performance. Inozyme Pharma Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Inozyme Pharma market risk premium is the additional return an investor will receive from holding Inozyme Pharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Inozyme Pharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Inozyme Pharma's performance over market.| α | 3.39 | β | 2.14 |
Inozyme Pharma expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Inozyme Pharma's Buy-and-hold return. Our buy-and-hold chart shows how Inozyme Pharma performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Inozyme Pharma Market Price Analysis
Market price analysis indicators help investors to evaluate how Inozyme Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Inozyme Pharma shares will generate the highest return on investment. By understating and applying Inozyme Pharma stock market price indicators, traders can identify Inozyme Pharma position entry and exit signals to maximize returns.
Inozyme Pharma Return and Market Media
The median price of Inozyme Pharma for the period between Fri, Mar 7, 2025 and Thu, Jun 5, 2025 is 1.06 with a coefficient of variation of 72.25. The daily time series for the period is distributed with a sample standard deviation of 1.18, arithmetic mean of 1.63, and mean deviation of 0.92. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Douglas Treco of 1710 shares of Inozyme Pharma at 4.45 subject to Rule 16b-3 | 04/07/2025 |
2 | Buy Rating on Inozyme Pharma Promising Potential of INZ-701 and Market Opportunity - TipRanks | 04/08/2025 |
3 | Disposition of 4407 shares by Bolte Axel of Inozyme Pharma at 0.98 subject to Rule 16b-3 | 05/15/2025 |
4 | Shareholder Alert The Ademi Firm investigates whether Inozyme Pharma, Inc. is obtaining a Fair Price for its Public Shareholders | 05/16/2025 |
5 | Inozyme Pharma finds buyer in BioMarin after strategic review | 05/19/2025 |
6 | Biotech Stock Roundup BMRN to Acquire INZY, NVAX Gains on Vaccine Approval More | 05/22/2025 |
7 | Acquisition by Bolte Axel of 152823 shares of Inozyme Pharma at 0.98 subject to Rule 16b-3 | 05/23/2025 |
8 | SHAREHOLDER INVESTIGATION Halper Sadeh LLC Investigates INZY, TXNM, SVT, PTIX on Behalf of ... | 05/27/2025 |
9 | Acquisition by Hopfner Robert Lorne of 228702 shares of Inozyme Pharma at 6.25 subject to Rule 16b-3 | 05/29/2025 |
10 | inozyme pharma announces executive bonuses amid merger plans By Investing.com - Investing.com Nigeria | 06/02/2025 |
About Inozyme Pharma Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Inozyme or other stocks. Alpha measures the amount that position in Inozyme Pharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Inozyme Pharma Upcoming Company Events
As portrayed in its financial statements, the presentation of Inozyme Pharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Inozyme Pharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Inozyme Pharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Inozyme Pharma. Please utilize our Beneish M Score to check the likelihood of Inozyme Pharma's management manipulating its earnings.
| 27th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Inozyme Pharma
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Inozyme Stock Analysis
When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.